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INTRODUCTION
The glottis is the most commonly involved subsite of laryngeal 
cancer (1). Early appearing subjective symptoms of voice change 
and throat discomfort frequently bring the patients to medical 
attention at early stages of glottic cancer, and the lesions are 
easily visible by laryngoscopic evaluation, which enables early 
suspicion and diagnosis. The paucity of the lymphatic capillary 
beneath the glottic mucosa usually limits the incidence of lymph 
node metastasis below 5%, if diagnosed early. Based on this un-
derlying pathophysiology, high local control and survival rates in 
the range of 75-95% could be achieved by either surgery alone 
or radiation therapy (RT) alone (2-4). RT generally has the ad-
vantages of wider applicability and higher likelihood of preserv-
Objectives. The authors would report the results of definitive radiation therapy (RT) for early glottic cancer by two different 
radiation dose schedules.
Methods. From February of 1995 till June of 2008, 157 patients with T1-2N0 glottic cancer were treated with curative RT 
at Samsung Medical Center. All patients had squamous cell carcinoma, and there were 89 patients (56.7%) with T1a, 
36 (22.9%) with T1b, and 32 (20.4%) with T2. Two different radiation dose schedules were used: 70 Gy in 35 fractions 
to 64 patients (40.8%, group A); and 67.5 Gy in 30 fractions to 93 patients (59.2%, group B). The median treatment 
durations were 50 days (range, 44 to 59 days) and 44 days (range, 40 to 67 days) in the groups A and B, respectively.
Results. The median follow-up durations were 85 and 45 months for the groups A and B. No severe late complication of 
RTOG grade 3 or higher was observed, and there was no difference in acute or chronic complication between the 
groups. Twenty-four patients experienced treatment failure: local recurrence only in 19 patients; regional recurrence 
only in one; combined local and regional recurrence in four; and systemic metastasis in none. The overall 5-year dis-
ease-free survival and disease-specific survival rates were 84.7% and 94.8%. The disease-free survival rate in the group 
B was better (78.3% vs. 90.8%, P=0.031). This difference was significant only in T1 stage (83.4% vs. 94.6%, P= 
0.025), but not in T2 (62.7% vs. 60.6%, P=0.965). Univariate analysis showed that the tumor extent, cord mobility, 
T-stage, and the dose schedule had significant influence on the disease-free survival, and multivariate analysis showed 
that only the tumor extent and the dose schedule were associated with the disease-free survival.
Conclusion. Superior disease-free survival could be achieved by 2.25 Gy per fraction without increased toxicity over shorter 
RT duration, when compared with 2.0 Gy per fraction.
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ing serviceable voice quality than surgery (5). Several factors af-
fecting the clinical outcomes have been reported in RT, includ-
ing the dose per fraction and the dose schedules (6). Authors 
retrospectively analyzed the clinical outcomes and the influenc-
es of possible prognostic factors in early glottic cancer treated by 
two different radiation dose schedules, and would report our 
experience. 
MATERIALS AND METHODS
Patients
From February of 1995 till June of 2008, the number of patients 
with T1-2N0M0 glottic caner, who were given curative RT, was 
157. The staging work-up included thorough history and physi-
cal examination, chest X-ray, neck CT scans, PET or PET-CT 
scans, and routine blood tests. All the patients had squamous 
cell carcinoma and underwent laryngomicroscopy for histologic 
confirmation. 
Radiation therapy
After taking CT simulation at the treatment posture, the radia-
tion dose plan was made on each individual patient. The radia-
tion target volume routinely included the upper border of the 
thyroid cartilage at the top and the lower border of the cricoid 
cartilage at the bottom, and minimum of 1-1.5 cm margins were 
put around all the clinically known disease extent of the individ-
ual patient. Anterior paired wedge beam arrangement with 4- or 
6-MV photons from linear accelerators were used in all the pa-
tients. The radiation portal sizes varied from 5×5 cm
2 to 7×8 
cm
2 depending on the patients’ contour. Two different radiation 
dose schedules were used along the study duration: 70 Gy in 35 
fractions over 7 weeks by daily 2.0 Gy to 64 patients (40.8%) 
treated from February of 1995 till May of 2001 (group A); and 
67.5 Gy in 30 fractions over 6 weeks by daily 2.25 Gy to 93 pa-
tients (59.2%) treated from June of 2001 till June of 2008 (group 
B). The biologically effective doses (BED) of acute and late re-
sponding tissues were similar between the groups: 84.0 Gy10 and 
116.7 Gy3 in the group A; and 82.7 Gy10 and 118.1 Gy3 in the 
group B. 
Follow-up
Follow-up evaluation with laryngoscopy and physical examina-
tion were done regularly on an out-patient basis, and the re-
sponse evaluation was done in 1 month of completion of RT. 
The follow-up intervals were 2-3 months’ during the first year, 
3-6 months’ during the second to third years, and 6-12 months 
thereafter. Chest X-rays were taken at least once a year, and CT 
scan, PET-CT or other laboratory tests were done whenever 
clinically indicated. The events of side effects, recurrence or me-
tastasis, death, and occurrence of the second malignancy were 
recorded during the follow-up.
Statistical analysis
The dates of the RT start were the bases of all the observation 
durations. The survival rates were calculated by Kaplan-Meier 
method, and their comparisons were done by log-rank test. The 
comparisons among the groups were done by Student t-test, and 
Cox regression test was used for multivariate analysis.
RESULTS
Patients’ characteristics
The patients’ age ranged from 35 years to 83 years with the me-
dian age of 62 years, with the male preponderance (151, 96.2%). 
The laryngomicroscopy was done only for diagnostic evaluation 
and biopsy in 116 patients (73.8%), and for potentially curative 
resection in 41 (26.2%). Clinical T-stages based on laryngomi-
croscopic evaluation were T1a in 89 patients (56.7%), T1b in 36 
(22.9%), and T2 in 32 (20.4%), respectively. The median overall 
treatment durations were 50 days (range, 47 to 59 days) and 44 
days (range, 40 to 67 days) in the groups A and B. There was no 
significant difference in the distribution of the characteristics be-
tween the treatment groups, except sex (Table 1). 
Table 1. Patients characteristics by fraction size
Characteristics
Total 
(n=157)
2.0 Gy/fraction 
(n=64)
2.25 Gy/fraction 
(n=93)
P-value*
Age (years) 62 (35-83) 63 (44-83) 62 (35-82) 0.062
Sex 0.042
  Male 151 (96.2) 59 (92.2) 92 (98.9)
  Female 6 (3.8) 5 (7.8) 1 (1.1)
Anterior commissure 0.742
  Involved 65 (41.4) 25 (39.1) 40 (43.0)
  Uninvolved 92 (58.6) 39 (60.9) 53 (57.0)
Tumor extent 0.927
  Glottic only 128 (81.5) 52 (81.3) 76 (81.7)
  Supraglottic 12 (7.6) 5 (7.8) 7 (7.5)
  Subglottic 13 (8.3) 6 (9.4) 7 (7.5)
  Supra- &
    subglottic
4 (2.5) 1 (1.6) 3 (3.2)
T-stage 0.667
  T1a 89 (56.7) 36 (56.3) 53 (57.0)
  T1b 36 (22.9) 13 (20.3) 23 (24.7)
  T2 32 (20.4) 15 (23.4) 17 (18.3)
Laryngomicrosurgery 0.198
  Diagnostic 116 (73.8) 51 (79.7) 65 (69.9)
  Therapeutic 41 (26.2) 13 (20.3) 28 (30.1)
Differentiation 0.303
  Well  52 (33.1) 17 (26.6) 35 (37.6)
  Moderately  25 (15.9) 12 (18.7) 13 (14.0)
  Poorly   1 (0.6) 0 (0) 1 (1.1)
  Unknown 79 (50.3) 35 (54.7) 44 (47.3)
Treatment duration (days) 50 (47-59) 44 (40-67)
Values are presented as median (range) or number (%).
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Side effects
Vast majority of the patients experienced radiation mucositis 
and dermatitis presenting from 2 weeks of RT start, and com-
plained of throat pain on swallowing and voice change. These 
acute side effects were, however, grade 2 or lower, and controlled 
with symptomatic management including analgesics medication. 
There was no significant difference in grade 2 mucositis incidence 
between the groups: two in the group A (3.1%); and six in the 
group B (6.5%). No delayed complication of grade 2 or higher 
was observed during the follow-up.
Local control, survival, and prognostic factors
The median follow-up durations were 85 and 45 months in the 
groups A and B, respectively. Local control, evaluated in 1 month 
of completion of RT, was achieved in all the patients. Recurrence, 
however, was observed in 24 patients (15.3%) during the follow-
up: local relapse only in 19 patients (12.1%) at the median fol-
low-up of 8 months (range, 3 to 48 months); combined local 
and regional recurrence in four (2.5%) at the median follow-up 
of 13 months (range, 6 to 35 months); and regional recurrence 
only in one (0.6%) at 4 months (Table 2). There was no occur-
rence of distant metastasis during the follow-up. Twenty patients 
underwent salvage surgery, three received re-irradiation, and 
one abandoned further salvage therapy. Total laryngectomy was 
performed in seven patients.
  The disease-free, overall, and disease-specific survival rates at 
5 years in all the patients were 84.7%, 92.6%, and 94.8% (Fig. 
1). The tumor extent, vocal cord motility, T-stage, and the radia-
tion dose schedule were the significantly important factors affect-
ing the disease-free survival on univariate analyses, while the 
tumor extent and the radiation dose schedule remained as sig-
nificant factors on multivariate analyses (Table 3). The disease-
free survival rates at 5 years were 78.3% and 90.8% in the 
Table 2. Patterns of failure
Failure
2.0 Gy/ 
fraction
(n=64)
2.25 Gy/ 
fraction
(n=93)
Total
(n=157)
Median 
interval from 
radiotherapy 
(months)
Local only 13 (20.3) 6 (6.5) 19 (12.1) 8 (3-48) 
Combined
  local and 
  regional 
2 (3.1) 2 (2.2) 4 (2.5) 13 (6-35) 
Regional only 1 (1.6) 0 (0) 1 (0.6) 4 
Total 16 (25.0) 8 (8.6) 24 (15.3) 8 (3-48) 
Values are presented as number (%).
Fig. 1. Disease-free survival (A), overall survival (B), and disease-
specific survival (C) of the patients with early glottic cancer treated 
by definitive radiation therapy.
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groups A and B. There was a significant difference in the disease-
free survival rates in T1 stage (83.4% vs. 94.6%, P=0.025), but 
not in T2 stage (62.7% vs. 60.6%, P=0.965) based on the treat-
ment groups (Fig. 2). The disease-free survival rate at 5 years in 
those who received salvage therapy for recurrence was 75.0%.
Second malignancy
The second malignancy was diagnosed in 21 patients during the 
follow-up: stomach cancer in six (25.8%); hepatoma in four (19.0 
%); colorectal cancer in three (14.3%); lung cancer in three 
(14.3%); esophageal cancer in two (9.5%); prostate cancer in 
one (4.7%); tongue cancer in one (4.7%); and parotid cancer in 
one (4.7%) (Table 4). There was no difference in the incidence 
of second malignancy based on the radiation dose schedules.
DISCUSSION
In treating early glottic cancer, therapeutic options with the ca-
pability of voice preservation include open partial laryngectomy, 
transoral laser excision, and RT. Favorable outcomes could be 
achieved by any of these modalities, and the local control rates 
at 5 years ranged from 85% to 95% in T1, and from 60% to 
80% in T2 stages (2-4, 7-9). The choice of treatment modality 
usually depends on T-stage, anterior commissure involvement, 
preference of patient and physician, general status of patient (5, 
10). Among these therapies, RT and transoral laser excision are 
equally recommended for early glottic cancer in general. How-
ever, RT may be preferred to surgery if the tumor size becomes 
bigger, considering the post-therapy voice quality, while open 
partial laryngectomy is usually considered for treating local re-
currence following other modalities (5). 
  Usual recommendation in RT for early glottic cancer was to 
give higher radiation dose to T2 stage than to T1. T2 stage differs 
from T1 in two aspects: the extent of tumor outside the true vo-
cal cord; and/or the impaired vocal cord motility. These rather 
arbitrary differentiation points, however, are subject to inter-ob-
server variation and not always reliable even after laryngomicro-
scopic evaluation under general anesthesia. The current study 
employed the same dose schedules to both T1 and T2 stages as-
suming that there might have been, more or less, subjective vari-
ations in the T-stage assignment, and better local control rates at  Table 3. Prognostic factors analyses
Parameters
Disease-free survival Overall survival
Univariate Multivariate Univariate Multivariate
Sex 0.897 0.976 0.836 0.964
Age 0.126 0.235 0.024 0.505
Anterior commissure
 involvement
0.362 0.366 0.974 0.928
Tumor extent 0.000 0.019 0.355 0.536
Mobility 0.036 0.923 0.315 0.102
T-stage 0.000 0.330 0.395 0.959
Aim of laryngomicro-
  surgery
0.063 0.125 0.639 0.848
Differentiation 0.662 0.171 0.382 0.148
Dose schedule 0.041 0.011 0.126 0.076
Table 4. Incidence of second malignancy
Disease 2.0 Gy/fraction 2.25 Gy/fraction Total
Stomach cancer 4 (36.4) 2 (20.0) 6 (25.8)
Hepatoma 1 (9.1) 3 (30.0) 4 (19.0)
Colorectal cancer 2 (18.2) 1 (10.0) 3 (14.3)
Lung cancer 1 (9.1) 2 (20.0) 3 (14.3)
Esophageal cancer 1 (9.1) 1 (10.0) 2 (9.5)
Prostate cancer 1 (9.1) 0 (0) 1 (4.7)
Tongue cancer 0 (0) 1 (10.0) 1 (4.7)
Parotid cancer 1 (9.1) 0 (0) 1 (4.7)
Total 11 (100) 10 (100) 21 (100)
Values are presented as number (%).
Fig. 2. Impact of fraction size by T-stage: disease-free survival rates at 5 years were 83.4% and 94.6% in the groups A and B of T1 patients 
(P=0.025) (A), and 62.7% and 60.6% in the groups A and B of T2 patients (P=0.965), respectively (B).
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5 years were achieved in T1 stage than in T2 (90.2% vs. 61.4%, 
P<0.001). Our local control rates, especially in T1 stage, could 
be favorably comparable to the other reports that usually applied 
differential total doses based on the clinical T-stages. This implies 
that there might have been a dose-response relationship within 
T1 stage disease (11), and that the stage assignment, if based 
mainly on the visual evaluation of the tumor extent and the cord 
motility, has the tendency of understaging of T2 disease to T1.
  Several patient-related prognostic factors with respect to the 
local control by RT were reported, and included histologic differ-
entiation, pre-therapy hemoglobin level, p53 expression, T-stage, 
anterior commissure involvement, vocal cord motility, and tu-
mor extent. The prognostic significance of the tumor extent, vo-
cal cord motility, T-stage, and the radiation dose schedule on the 
disease-free survival were affirmed by the current study. Some 
reported that the anterior commissure involvement was related 
with the increased risks of local failure and necrosis following ei-
ther RT or surgery, however, there were controversial opinions (5, 
6, 12-14). No significance was seen based on the anterior com-
missure involvement in the current study.
  Among the several RT-related prognostic factors, the duration 
of RT and the fractional radiation dose are very important. It 
was reported that the tumor doubling time in head and neck 
cancers could be as short as 3-5 days during the anti-cancer che-
motherapy or RT courses, which could lead to unfavorable local 
control (15, 16). To overcome the accelerated repopulation, 
shortening of the RT duration is desirable. Early glottic cancer, 
as it needs relatively small and limited radiation volume, could 
serve an ideal model to investigate the influence of the RT dura-
tion over the local control rate. The RT duration and the fraction 
size are very closely related, and the risk of delayed morbidity 
should be carefully considered when increasing the fractional 
radiation dose when shortening the RT duration. Several studies 
already suggested that the fractional dose higher than 3.0 Gy 
could lead to unacceptably high level of severe complications 
(17-19). Since 1990, there have been several reports on the frac-
tion size and the local control rate (Table 5) (6, 20-23). Le et al. 
(21) applied 4 different fraction sizes (<180 cGy, 180-199 cGy, 
200-224 cGy, and ≥225 cGy), and found there was no differ-
ence in local control rates in T1 stage, while significantly better 
local control achieved in T2 stage ≥ by 225 cGy (100%) when 
compared with <180 cGy (44%). Yu et al. (23) reported the 
similar effect in T1 stage (84% by >200 cGy/fraction and 65.5% 
by 200 cGy/fraction). Yamazaki et al. (6) prospectively compared 
the impact of the fraction sizes, and reported that the local con-
trol rates were 77% by 200 cGy and 92% by 225 cGy with no 
significant difference in the incidence of side effects. Rudoltz et 
al. (24) reported decreasing local control rates with increasing 
RT durations: 100% if RT was completed within 42 days; 91% 
for 43-46 days; 74% for 47-50 days; 65% for 51-54 days; and 
50% for 55-66 days (P=0.0001). Fein et al. (20) also reported 
that the RT duration shorter than 50 days was advantageous 
with respect to the local control rates at 2 years (92% vs. 82%, 
P=0.07). The local control rates in the current study were favor-
ably comparable to the others, while there was no increase of 
the complication rates according to the fractional doses with no 
grade 3 or higher side effects.
  The treatment failures after RT for early glottic cancer were 
known to occur mostly in the local area, while the regional fail-
ure rates were 5-20% (25, 26), and surgery should be consid-
ered for salvaging the loco-regional failures following RT. Nibu 
et al. (27) applied partial laryngectomy as salvage modality, and 
reported the 5-year survival and larynx-preservation rates of 
86%. Le et al. (21), following transoral laser surgery or open 
partial laryngectomy, reported the local control rates of 83% in 
T1 stage, and 74% in T2 stage, and the ultimate local control 
Table 5. Reports of local control according to fraction size and treatment time
Investigator
Median follow-up 
(months)
Fraction size (Gy)  Treatment duration Total dose (Gy)
Local control (5 years, %)
T1 T2
Yamazaki et al. (6) 60  2.0 6-6.6 weeks 60/66 76/78 NA
2.25 5-5.6 weeks 56.25/63 91/92
Fein et al. (20) 82  2.0 <50 days 66 (T1) 92
≥50 days 69 (T2) 79
Le et al. (21) 116  <1.8 34-75 days 63 (T1) 79 44
1.8-1.19 65.2 (T2) 92 79
2.0-2.24 81 73
≥2.25 94 100
Sakata et al. (22)  63  2.0 44-57 days 64 80 64
1.72 bid 22-26 days 55/58.5 87/94 68/56
Yu et al. (23) 84  >2.0 26-46 days 50/65.25 84 NA
2.0 66 65.60
Current study 57.5  2.0 7 weeks 70 83 63
2.25 6 weeks 67.5 95 61
NA, not available.Kim TG et al.: RT for Early Glottic Cancer    99
rates at 10 years of 96% in T1, and 91% in T2 stages. In the cur-
rent study, there were total of 24 patients with loco-regional re-
currences among 157 patients (crude rate, 15.3%), and 3/4 of 
them were salvaged following salvage therapy mainly by surgery. 
As seven patients underwent total laryngectomy, the crude lar-
ynx-preservation rate among the entire patients was 95.5%. 
  Surveillance of the second malignancy is very important as 
the patients should have already been exposed to the carcino-
gens of the upper aerodigestive tracts, and they have high ex-
pectancy of long-term survival following RT. The reported inci-
dence of the second malignancy is in the range of 20% to 25%, 
which usually becomes greater with longer follow-up duration 
(28, 29). Franchin et al. (30) reported that the incidence of the 
second malignancy among the patients with early glottic cancer 
was 22.2%, commonly involving the respiratory tract, the head/
neck, and the uro-genital tract. The second cancer incidence re-
ported by Yamazaki et al. (6) was 25%, where the stomach, the 
head/neck, the esophagus, and the lung were commonly in-
volved. The authors observed 21 patients who developed the 
second malignancy (13.3%) at median 37 months’ follow-up, 
and this incidence might increase with longer-term follow-up. 
The organs of the second malignancy in the current study were 
the stomach, the liver, the colorectum, and the lung, which was 
more or less similar to Japanese reports.
  RT traditionally has served as a standard therapy for early 
glottic cancer with the high local control rates, a favorable voice 
quality, and the low complication rates. In the current study, the 
vocal cord mobility, the tumor extent and the fraction size were 
the significant factors for the disease-free survival. With the frac-
tional dose of 2.25 Gy, instead of 2.0 Gy per fraction, the au-
thors could deliver the equivalent biologic total dose during 
shorter duration, and achieve improved disease-free survival in 
the T1 stage at no increased toxicity. 
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
ported. 
REFERENCES
1. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosen-
berg’s cancer: principles & practice of oncology. 8th ed. Philadelphia: 
Lippincott Williams & Wilkins; 2008.
2. Akimoto T, Nonaka T, Kitamoto Y, Ishikawa H, Ninomiya H, Chika-
matsu K, et al. Radiation therapy for T2N0 laryngeal cancer: a retro-
spective analysis for the impact of concurrent chemotherapy on lo-
cal control. Int J Radiat Oncol Biol Phys. 2006 Mar;64(4):995-1001.
3. Kim WT, Nam JH, Kyuon BH, Wang SG, Kim DW. Radiotherapy for 
early glottic carinoma. J Korean Soc Ther Radiol Oncol. 2002 Dec; 
20(4):295-302.
4. Lee HS, Moon SR, Ahn KJ, Chung EJ, Suh CO, Kim GE, et al. The 
heterogeneity of T2NO glottic carcinoma treated by irradiation. J 
Korean Soc Ther Radiol. 1990 Dec;8(2):199-206.
5. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. 
Management of T1-T2 glottic carcinomas. Cancer. 2004 May;100(9): 
1786-92.
6. Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M. Radio-
therapy for early glottic carcinoma (T1N0M0): results of prospective 
randomized study of radiation fraction size and overall treatment 
time. Int J Radiat Oncol Biol Phys. 2006 Jan;64(1):77-82.
7. Garden AS, Forster K, Wong PF, Morrison WH, Schechter NR, Ang 
KK. Results of radiotherapy for T2N0 glottic carcinoma: does the 
“2” stand for twice-daily treatment? Int J Radiat Oncol Biol Phys. 
2003 Feb;55(2):322-8.
8. McCoul ED, Har-El G. Meta-analysis of impaired vocal cord mobility 
as a prognostic factor in T2 glottic carcinoma. Arch Otolaryngol Head 
Neck Surg. 2009 May;135(5):479-86.
9. Park JH, Paeng JP, Na HS, Lim KJ, Kwon SY, Jung KY, et al. Treat-
ment results of laser cordectomy and radiation therapy for early glot-
tic cancer. Korean J Otolaryngol-Head Neck Surg. 2002 Feb;45(2): 
159-63.
10. Dey P, Arnold D, Wight R, MacKenzie K, Kelly C, Wilson J. Radio-
therapy versus open surgery versus endolaryngeal surgery (with or 
without laser) for early laryngeal squamous cell cancer. Cochrane 
Database Syst Rev. 2002;(2):CD002027.
11. Agrawal N, Ha PK. Management of early-stage laryngeal cancer. 
Otolaryngol Clin North Am. 2008 Aug;41(4):757-69.
12. Marshak G, Brenner B, Shvero J, Shapira J, Ophir D, Hochman I, et 
al. Prognostic factors for local control of early glottic cancer: the 
Rabin Medical Center retrospective study on 207 patients. Int J Ra-
diat Oncol Biol Phys. 1999 Mar;43(5):1009-13.
13. Nozaki M, Furuta M, Murakami Y, Izawa Y, Iwasaki N, Takahashi H, 
et al. Radiation therapy for T1 glottic cancer: involvement of the an-
terior commissure. Anticancer Res. 2000 Mar-Apr;20(2B):1121-4.
14. Wolfensberger M, Dort JC. Endoscopic laser surgery for early glottic 
carcinoma: a clinical and experimental study. Laryngoscope. 1990 
Oct;100(10 Pt 1):1100-5.
15. Fowler JF. Fractionated radiation therapy after Strandqvist. Acta Ra-
diol Oncol. 1984;23(4):209-16.
16. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Wei-
jngaert D, Bolla M, et al. Accelerated fractionation (AF) compared 
to conventional fractionation (CF) improves loco-regional control in 
the radiotherapy of advanced head and neck cancers: results of the 
EORTC 22851 randomized trial. Radiother Oncol. 1997 Aug;44(2): 
111-21.
17. Harwood AR, Tierie A. Radiotherapy of early glottic cancer-II. Int J 
Radiat Oncol Biol Phys. 1979 Apr;5(4):477-82.
18. Randall ME, Springer DJ, Raben M. T1-T2 carcinoma of the glottis: 
relative hypofractionation. Radiology. 1991 May;179(2):569-71.
19. van der Voet JC, Keus RB, Hart AA, Hilgers FJ, Bartelink H. The im-
pact of treatment time and smoking on local control and complica-
tions in T1 glottic cancer. Int J Radiat Oncol Biol Phys. 1998 Sep; 
42(2):247-55.
20. Fein DA, Lee WR, Hanlon AL, Ridge JA, Curran WJ, Coia LR. Do 
overall treatment time, field size, and treatment energy influence lo-
cal control of T1-T2 squamous cell carcinomas of the glottic larynx? 
Int J Radiat Oncol Biol Phys. 1996 Mar;34(4):823-31.
21. Le QT, Fu KK, Kroll S, Ryu JK, Quivey JM, Meyler TS, et al. Influ-
ence of fraction size, total dose, and overall time on local control of 
T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys. 1997 Aug; 
39(1):115-26.
22. Sakata K, Someya M, Hori M, Nakata K, Takagi M, Hareyama M. 
Hyperfractionated accelerated radiotherapy for T1,2 glottic carcino-
ma: consideration of time-dose factors. Strahlenther Onkol. 2008 100    Clinical and Experimental Otorhinolaryngology   Vol. 5, No. 2: 94-100, June 2012 
Jul;184(7):364-9.
23. Yu E, Shenouda G, Beaudet MP, Black MJ. Impact of radiation thera-
py fraction size on local control of early glottic carcinoma. Int J Ra-
diat Oncol Biol Phys. 1997 Feb;37(3):587-91.
24. Rudoltz MS, Benammar A, Mohiuddin M. Prognostic factors for lo-
cal control and survival in T1 squamous cell carcinoma of the glottis. 
Int J Radiat Oncol Biol Phys. 1993 Aug;26(5):767-72.
25. Kim YH, Chai GY. Radiotherapy of early stage glottic cancer. J Kore-
an Soc Ther Radiol. 1997 Dec;15(4):315-20.
26. Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1-T2N0 
squamous cell carcinoma of the glottic larynx treated with radiation 
therapy. J Clin Oncol. 2001 Oct;19(20):4029-36.
27. Nibu K, Kamata S, Kawabata K, Nakamizo M, Nigauri T, Hoki K. 
Partial laryngectomy in the treatment of radiation-failure of early 
glottic carcinoma. Head Neck. 1997 Mar;19(2):116-20.
28. Fujita M, Rudoltz MS, Canady DJ, Patel P, Machtay M, Pittard MQ, 
et al. Second malignant neoplasia in patients with T1 glottic cancer 
treated with radiation. Laryngoscope. 1998 Dec;108(12):1853-5.
29. Narayana A, Vaughan AT, Fisher SG, Reddy SP. Second primary tu-
mors in laryngeal cancer: results of long-term follow-up. Int J Radiat 
Oncol Biol Phys. 1998 Oct;42(3):557-62.
30. Franchin G, Minatel E, Gobitti C, Talamini R, Vaccher E, Sartor G, et 
al. Radiotherapy for patients with early-stage glottic carcinoma: uni-
variate and multivariate analyses in a group of consecutive, un-
selected patients. Cancer. 2003 Aug;98(4):765-72.